<DOC>
	<DOCNO>NCT00501735</DOCNO>
	<brief_summary>This Phase II , non-randomized , open-label , single-arm trial conduct 50 site North America , Europe Australia . This study design assess objective response ( OR ) [ complete response ( CR ) partial response ( PR ) ] subject cutaneous manifestation CTCL requirement maintenance objective response least 28 day subject stage IIB , III , IVA CTCL . Additionally , study evaluate safety tolerability CTCL subject Stages IB , IIA , IIB , III , IVA treat oral forodesine .</brief_summary>
	<brief_title>Forodesine Treatment Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>Males nonpregnant female age ≥18 year ; Histologically confirm diagnosis CTCL , include mycosis fungoides and/or Sezary syndrome , documentation diagnosis histologic examination available ; Subjects CTCL stag IB , IIA , IIB , III , IVA screen visit ( i.e . stage refers stage study entry ) persistent , progressive , recurrent disease follow treatment least three form systemic therapy , one must oral bexarotene , unless treatment oral bexarotene tolerate medically contraindicate ; Anticipated life expectancy great 6 month ; Performance status 0 , 1 , 2 Eastern Cooperative Oncology Group ( ECOG ) criterion ; Females childbearing potential must negative serum pregnancy test within 14 day prior initiation study treatment ; Females childbearing potential sexually active male , indicate , must willing able use method ( ) contraception adequate prevent minimize risk pregnancy duration study ; Written inform consent participate study . Proven suspect extracutaneous visceral CTCL involvement ( M1 ) ( CTCL stage IVB ) ( note : presence lymphadenopathy permit ) ; Previous treatment Forodesine ; ECOG performance status &gt; 2 ; Concomitant use anticancer therapy immune modifier ; Concomitant use investigational agent device ; Concurrent treatment antiCTCL therapy , radiation therapy [ topical corticosteroid ( class 1 2 prohibit ) low dose oral corticosteroid ( ≤10 mg/day prednisone equivalent ) exclude , use , must stable dose schedule four week immediately prior study entry ] ; Use previous therapy CTCL within timeframes specify : 1 . Phototherapy previous 30 day ; 2 . Electron beam therapy , photopheresis , systemic anticancer therapy , interferon therapy , investigational therapy previous 30 day ; 3 . Oral retinoid ( include bexarotene ) previous 30 day 4 . Alemtuzumab ( Campath ) monoclonal antibody within previous 30 day 5 . Vorinostat HDAC inhibitor within previous 30 day 6 . Any investigational therapy within previous 30 day ; ALT AST &gt; 3 time ULN alkaline phosphatase &gt; 2 time ULN ; Calculated creatinine clearance ≤50 mL/min serum creatinine ≥1.8 mg/dL ; Serum potassium &lt; 3.3 mg/dL &gt; 5.5 mg/dL ; Evidence clinically significant ( uncontrolled ) hypo hyperthyroidism ; Recent ( past 6 month ) medically significant cardiac event ( i.e. , myocardial infarction , cardiac surgery ) ; Presence congestive heart failure ( NYHA class IV ) angina ( NYHA class IV ) presence medically significant dysrhythmia ; Presence follow ECG finding : 1 . Congenital long QT syndrome ; 2 . QTc interval &gt; 480 msec ( Bazett 's correction ) ; Presence uncontrolled hypertension manifest systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥90 mmHg ; Hemoglobin &lt; 9.0 gm/dL ( intermittent red blood cell transfusion permit ) ; Absolute neutrophil count &lt; 1500 cells/mm3 ; Platelet count &lt; 75,000/mm3 ; Requirement neutrophil platelet growth factor therapy administration therapy previous 30 day ; CD4 count &lt; 200/mm3 ; Documented current active infection HIV , Hepatitis B , Hepatitis C , and/or CMV ; Presence uncontrolled bacterial viral infection ( subject may receive chronic antimicrobial therapy ) ; , History culturedocumented bacteremia previous 2 week ; Recent ( i.e. , past 2 week ) change dose regimen medication use chronic nononcologic condition reason worsen chronic illness ( change dose chronic medication associate improvement chronic illness exclusionary ) ; Presence acute chronic nononcologic disease , opinion investigator , medically uncontrolled ; Coexistent second malignancy history prior malignancy within previous 5 year [ exclude basal cell squamous cell carcinoma skin cervical neoplasia ( carcinomainsitu ) treat curatively ] . Surgically resect nonmelanomatous skin cancer ( nonCTCL ) evidence recurrence previous 6 month permit ; , Any significant medical psychiatric condition , opinion investigator , might prevent subject complying require study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>T-Cell</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Forodesine</keyword>
	<keyword>Mycosis Fungoides</keyword>
</DOC>